Neuralstem, Inc. announced that Dr. Shinn-Zong Lin, Superintendent at China Medical University Hospital, will present results from a study entitled, “Intracerebral Implantation of Adherent Human Neural Stem Cells (or Neurals Progenitor Cells or “NPCs”) to Reverse Motor Deficits in Chronic Stroke Rats,” at the Stem Cells USA & Regenerative Medical Conference in Philadelphia, PA, on September 14, 2010.
“We are encouraged by Dr. Lin’s findings with our stem cells, which represent a significant milestone for Neuralstem,” said Richard Garr, Neuralstem CEO and President. “Unlike our programs in ALS and chronic spinal cord injury, in which our cells are transplanted into the spinal cord, we will treat stroke-related movement disorders by direct transplantation into the brain. We are developing stroke clinical programs both in the U.S. and in Taiwan, and hope to start our first trial in 2011.”
The company also announced that CEO and President, Richard Garr, will take part in a panel at the conference with other industry leaders entitled, “IP Issues and Licensing Arrangements,” on September 14, 2010. The panel will discuss intellectual property patent law and licensing issues, as well as how to manage both IP issues and biotech licensing agreements.